Drs. Galsky, Kollmeier, and Sfakianos received a modest honorarium from Frontline Medical Communications for their participation in this roundtable.
The faculty was solely responsible for the content presented in the videos.
Dr. Galsky discloses that he owns stocks in Rappta Therapeutics. He is a consultant or advisor for Aileron Therapetuics, AstraZeneca, Astellas Pharma, BioMotiv, Bristol-Myers Squibb, Dendreon, Dracen, Dragonfly Therapeutics, EMD Serono Genentech, GlaxoSmithKline, Incyte, Inovio Pharmaceuticals, Janssen, Lilly, Merck, Novartis, NuMab, Pfizer, and Seattle Genetics. His institution has received research funding from AstraZeneca, Bristol-Myers Squibb, Dendreon, Genentech/Roche, Janssen Oncology, Merck, and Novartis. Dr. Galsky also has patents, royalties, or other intellectual property for methods and compositions for treating cancer and related methods.
Dr. Kollmeier has no potential conflicts of interest to disclose.
Dr. Sfakianos has no potential conflicts of interest to disclose.